Previous 10 | Next 10 |
Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release. Blarcamesine likely scavenges peroxynitrite. I...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Athira Pharma, Inc. (NasdaqGS: ATHA). On June 17, 2021, the Company disclosed that the...
BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced, based on the preliminary vote count provided...
Athira Board Unanimously Recommends Shareholders Vote “FOR” its Highly Qualified Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE proxy card BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma...
BOTHELL, Wash., May 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of preclinical data on two s...
ATHIRA PHARMA INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA ATHIRA PHARMA INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & F...
Athira Pharma press release (NASDAQ:ATHA): Q1 GAAP EPS of -$0.56 beats by $0.01. Cash, cash equivalents and investments were $301.2 million as of March 31, 2022, compared with $319.7 million as of December 31, 2021. For further details see: Athira Pharma GAAP EPS of -$0.56 beats by $0.0...
BOTHELL, Wash., May 12, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the company’s financial results for th...
Urges Shareholders to Vote TODAY “FOR” Athira’s Highly Qualified, Independent Director Nominees – Joseph Edelman, John M. Fluke, Jr. and Grant Pickering – on the WHITE Proxy Card BOTHELL, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- ...
– Study duration increased from 6 months to 18 months of open label treatment with fosgonimeton – BOTHELL, Wash., May 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small m...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...